Compounding the problem
Shortages and the sky-high cost of the new weight loss drugs has led to an explosion of compounded alternatives sold online, through telehealth sites and in compounding pharmacies. Unfortunately, most of these products haven't been evaluated by the Food and Drug Administration for safety, effectiveness, or quality. A new study in JAMA found that more than 40% of 317 websites that were selling semaglutide (Wegovy, Ozempic) without a prescription belonged to illegal pharmacy operations. Use of these products can lead to hospitalizations because the medications contain incorrect active ingredients and incorrect dosing.
In addition, an article in JAMA Health Forum reports that when researchers looked at 79 websites selling compounded GLP-1s -- usually semaglutide and tirzepatide -- 57% didn't say their products were not FDA approved, almost half didn't report the drug's risks (adverse effects, warnings, precautions and contraindications) and more than 40% overstated benefits.
We're very enthusiastic about the true benefits of FDA-approved weight-loss drugs, including Wegovy, Ozempic, Saxenda, Zepbound. But they're not for everyone and must be combined with lifestyle changes that help you shed pounds and keep them off, including stress management, a diet focused on fresh produce, fatty fish and 100% whole grains, lots of physical activity, especially strength building, and a posse and a sense of suppose to help keep you on track.
Please, get weight-loss medications through FDA-approved outlets -- and if you cannot access these medications, don't give up your goal of a healthier weight. Check out the info and support we provide through LongevityPlaybook.com's free newsletter and in "The Great Age Reboot."
Dr. Mike Roizen is the founder of www.longevityplaybook.com, and Dr. Mehmet Oz is global advisor to www.iHerb.com, the world's leading online health store. Roizen and Oz are chief wellness officer emeritus at Cleveland Clinic and professor emeritus at Columbia University, respectively. Together they have written 11 New York Times bestsellers (four No. 1's).
(c)2025 Michael Roizen, M.D.
Distributed by King Features Syndicate, Inc.
(c) 2025 Michael Roizen, M.D. Distributed by King Features Syndicate, Inc.
Comments